FO
ALPN

FT Options’s Alpine Immune Sciences Inc ALPN Stock Holding History

FT Options’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,361
Closed -$63K – 302
2017
Q1 		$63K Sell
5,361
-3,389
-39% -$34.3K 0.08% 140
2016
Q4 		$78K Buy
+8,750
New +$174K 0.09% 115

Other funds holding ALPN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

FT Options's ALPN Position: Q2 2017 in Review

FT Options sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2017, closing a stake of 5,361 shares — an estimated $63K sold.

FT Options first reported a position in ALPN in Q4 2016 and held it in 2 quarters. The position peaked at $78K in Q4 2016. 26 funds tracked by Wall St. Rank hold ALPN as of Q2 2017.

  • FT Options reported no remaining Alpine Immune Sciences Inc position as of Q2 2017 after selling out during the quarter.
  • FT Options sold 5,361 Alpine Immune Sciences Inc shares in Q2 2017, an estimated $63K.
  • FT Options first reported a position in Alpine Immune Sciences Inc in Q4 2016 and held it in 2 quarters.
  • FT Options's Alpine Immune Sciences Inc position peaked at $78K in Q4 2016.
  • 26 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2017.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.